It was a 40-week, randomized, open-label, active-controlled phase 3 trial in 1,879 adults with type 2 diabetes inadequately controlled on metformin, comparing three tirzepatide doses with a comparator dose of injectable semaglutide
Because the results come from different clinical trials, we cant directly compare them or say one is definitely better, it depends on safety, approval status, and whats suitable for the individual
Slow and steady wins the race Of course, behaviour change is hard too but with the right support (mainly psychological), long-term change is possible
If mood symptoms are new, call your healthcare team sooner rather than later